Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1958 1
1962 1
1963 1
1988 3
1989 5
1990 6
1991 1
1992 6
1993 8
1994 7
1995 9
1996 13
1997 14
1998 18
1999 19
2000 35
2001 26
2002 50
2003 88
2004 70
2005 38
2006 33
2007 29
2008 23
2009 25
2010 34
2011 30
2012 17
2013 32
2014 25
2015 13
2016 12
2017 10
2018 9
2019 7
2020 7
2021 5
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 15389438

688 results

Results by year

Filters applied: . Clear all
Page 1
Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ, Kim DW, Lee S, Min CK, Goh HG, Kim SH, Lee JY, Kim YL, Kim HJ, Kim HJ, Lee JW, Kim TG, Min WS, Kim CC. Kim YJ, et al. Biol Blood Marrow Transplant. 2004 Oct;10(10):718-25. doi: 10.1016/j.bbmt.2004.06.033. Biol Blood Marrow Transplant. 2004. PMID: 15389438 Free article. Clinical Trial.
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ. DeAngelo DJ, et al. Clin Cancer Res. 2004 Aug 1;10(15):5065-71. doi: 10.1158/1078-0432.CCR-03-0580. Clin Cancer Res. 2004. PMID: 15297408
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia. Iacobucci I, et al. Clin Cancer Res. 2006 May 15;12(10):3037-42. doi: 10.1158/1078-0432.CCR-05-2574. Clin Cancer Res. 2006. PMID: 16707599 Clinical Trial.
688 results